Can you provide the last earnings date for MONTE ROSA THERAPEUTICS INC?
MONTE ROSA THERAPEUTICS INC (GLUE) last reported earnings on 3/12/2026.
MONTE ROSA THERAPEUTICS INC (GLUE) Earnings History & Surprises
NASDAQ:GLUE • US61225M1027
Current stock price
16.02 USD
-0.02 (-0.12%)
At close:
16.02 USD
0 (0%)
After Hours:
GLUE Earnings overview
Past quarterly earnings results for MONTE ROSA THERAPEUTICS INC (GLUE), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 6, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.36
- Revenue Estimate
- 15.816M
Last Reported
Most Recent- Release Date
- Mar 12, 2026
- Period
- Q3 / 2025
- EPS Reported
- -$0.33
- EPS Surprise
- 13.20%
- Revenue Surprise
- 130.97%
Beat Rate
Last 8 Quarters 81%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.33 | -0.38 | 13.20% | -13.79% | 12.768M | 5.528M | 130.97% | 38.54% |
| Q2 2025 | -0.15 | -0.39 | 61.87% | 65.12% | 23.194M | 11.016M | 110.55% | 394.01% |
| Q1 2025 | 0.56 | -0.34 | 262.91% | 205.66% | 84.929M | 15.586M | 444.91% | 7,882.05% |
| Q4 2024 | 0.23 | -0.02 | 1,080.39% | 139.66% | 60.647M | 11.611M | 422.32% | - |
| Q3 2024 | -0.29 | -0.50 | 41.55% | 58.57% | 9.216M | 2.673M | 244.78% | - |
| Q2 2024 | -0.43 | -0.55 | 21.93% | 39.44% | 4.695M | 1.376M | 241.21% | - |
| Q1 2024 | -0.53 | -0.58 | 9.30% | 18.46% | 1.064M | 1.428M | -25.49% | - |
| Q4 2023 | -0.58 | -0.34 | -69.89% | 7.94% | 15.453M | -100.00% | - | |
| Q3 2023 | -0.70 | -0.74 | 5.18% | -20.69% | - | - | ||
| Q2 2023 | -0.71 | -0.71 | 0.56% | -24.56% | - | - | ||
| Q1 2023 | -0.65 | -0.69 | 6.17% | -27.45% | - | - | ||
| Q4 2022 | -0.63 | -0.64 | 0.95% | 32.26% | - | - | ||
| Q3 2022 | -0.58 | -0.61 | 5.21% | -34.88% | - | - | ||
| Q2 2022 | -0.57 | -0.55 | -3.39% | 84.30% | - | - | ||
| Q1 2022 | -0.51 | -0.53 | 4.21% | - | - | - | ||
| Q4 2021 | -0.93 | -0.51 | -82.96% | - | - | - | ||
| Q3 2021 | -0.43 | -0.45 | 4.62% | - | - | - | ||
| Q2 2021 | -3.63 | -0.41 | -784.18% | - | - | - | ||
| Q1 2021 | - | - | - | - | ||||
| Q4 2020 | - | - | - | - | ||||
| Q3 2020 | - | - | - | - | ||||
| Q2 2020 | - | - | - | - | ||||
| Q1 2020 | - | - | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
4
Average EPS beat (4)
354.59%
Max EPS beat (4)
1,080.39%
Min EPS beat (4)
13.20%
Revenue beat statistics
Revenue beat (4)
4
Average Revenue beat (4)
277.19%
Max Revenue beat (4)
444.91%
Min Revenue beat (4)
110.55%
Analysis
In the last 4 quarters, GLUE has consistently beaten EPS estimates in all releases
GLUE has consistently beaten revenue estimates in all past 4 earnings releases
In the last 4 quarters, GLUE has beaten the EPS estimates by 354.6% on average.
In the last 4 quarters, GLUE has beaten the revenue estimates by 277.2% on average.
Related analysis
MONTE ROSA THERAPEUTICS INC / GLUE Earnings FAQ
Did MONTE ROSA THERAPEUTICS INC (GLUE) beat earnings estimates last quarter?
MONTE ROSA THERAPEUTICS INC (GLUE) beat EPS estimates and beat revenue estimates in the most recent quarter.
What percentage of the time does GLUE stock beat earnings estimates?
In the last 4 quarters, MONTE ROSA THERAPEUTICS INC (GLUE) has beaten EPS estimates in 4 out of 4 releases.